ReviewSeminars in oncology nursing2026
Quality and Safety Imperatives in the Identification and Management of Hereditary Cancer Syndromes.
Review in Seminars in oncology nursing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivesWe sought to provide an evidence review of the rapidly expanding technologies and sciences that have moved the field of hereditary cancers from niche to mainstream in current cancer care. This shift mandates that all oncology clinicians have foundational knowledge regarding the identification, testing, and management of patients and families at risk for hereditary cancer. Many cancers have established germline biomarker testing recommendations (breast, ovarian, pancreatic, metastatic prostate, colon), and in many of these cancer types, somatic biomarker tests are also considered standard of care. Unfamiliarity with the complexity of care in hereditary cancer leads to missed opportunities for cancer prevention and guideline-concordant genomic-informed care. Indeed, appropriately ordered, interpreted, and applied germline biomarker testing is a critical quality care indicator. Moreover, preventing harm from overlooked or inappropriate germline biomarker testing and incorrect result interpretation leads to optimal cancer prevention and effective cancer treatment. This is a central safety aspect in this rapidly changing landscape.
methodsA review of peer-reviewed literature.
resultsBased on the literature review, the Five Rights of Germline Biomarker Testing for Hereditary Cancer is offered as a quality and safety framework. Accurate construction and interpretation of the pedigree continue to be a critical risk assessment tool. A comprehensive view of patient factors, family history, tumor pathology, and somatic biomarker test results is essential for quality care in hereditary cancers.
conclusionOncology clinicians must be familiar with and refer to the most recent and updated versions of guidelines from reputable authorities, as the testing criteria shift frequently. IMPLICATIONS FOR NURSING PRACTICE: The five rights framework offers clinicians a guide to safe practice in this ever-changing landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.